Meyka Pro banner
Ascendis Pharma A/S

Stay Updated with the Latest Ascendis Pharma A/S ASND News in Real Time

Find ASND news now at Meyka AI. Stay informed with the latest Ascendis Pharma A/S stocks updates, including price news, market analysis, and expert insights.

ASNDNASDAQ
HealthcareBiotechnology
$253.29
$1.52(0.60%)
U.S. Market opens in 64h 53m
Japan’s Whistleblowers Face Retaliation: New Law Tightens Protections in December
📅 23 hours ago

Japan’s Whistleblowers Face Retaliation: New Law Tightens Protections in December

Japan’s amended Whistleblower Protection Act, effective December 2026, shifts burden of proof to employers and adds criminal penalties. But gaps remain for harassment and demotion cases.

Read more 12
Strides Pharma Stock Rallies 10% as USFDA Concludes Bengaluru Inspection
📅 1 day ago

Strides Pharma Stock Rallies 10% as USFDA Concludes Bengaluru Inspection

Strides Pharma shares surged 11% to ₹1,055.90 on the BSE on August 20, 2026. The rally followed news that the company’s flagship Bengaluru facility received a USFDA Establishment Inspection Report. That report confirms successful closure of a cGMP inspection conducted in May 2026. Heavy trading volumes accompanied the sharp intraday move. What the USFDA EIR…

Read more 12
Schott Pharma (ETR: 1SXP) Shares Jump 4% as Barclays Upgrades Stock to Overweight on Growth Inflection
📅 3 days ago

Schott Pharma (ETR: 1SXP) Shares Jump 4% as Barclays Upgrades Stock to Overweight on Growth Inflection

Schott Pharma shares jumped as much as 6.5% on August 18, 2026, hitting a new 52-week high of €23. Barclays upgraded the stock to “overweight” from “equal weight” and raised its price target to €27 from €16. Analyst Jonathon Unwin cited a genuine growth inflection after three years of declining earnings estimates. The upgrade reflects…

Read more 12
Gland Pharma (NSE: GLAND) Shares Surge 12% to 52-Week High of ₹2,969.90 After Strong Q1 FY27 Results
📅 10 days ago

Gland Pharma (NSE: GLAND) Shares Surge 12% to 52-Week High of ₹2,969.90 After Strong Q1 FY27 Results

Gland Pharma shares jumped nearly 12% on August 11, 2026, hitting a fresh 52-week high of ₹2,969.90 after the company reported strong Q1 FY27 results. Revenue rose 19.5% year on year to ₹1,800 crore, while net profit surged 47% to ₹317 crore. Strong US sales and rising CDMO revenue supported the quarter. The sharp rise…

Read more 12
Generic Zyrtec Recalled Over Heartburn Drug Contamination July 24
📅 28 days ago

Generic Zyrtec Recalled Over Heartburn Drug Contamination July 24

Generic Zyrtec recalled nationwide due to contamination with heartburn drug ranitidine. Four lot numbers affected. No illnesses reported yet. Check your bottles.

Read more 12
Eggs Salmonella Recall: Over 1.5 Million Dozen Eggs Pulled Across Six States
📅 28 days ago

Eggs Salmonella Recall: Over 1.5 Million Dozen Eggs Pulled Across Six States

More than 1.5 million dozen eggs have been recalled across the United States after concerns about possible Salmonella Enteritidis contamination. The voluntary recall, announced by the U.S. Food and Drug Administration (FDA) on July 22, 2026, covers eggs sold in six states through major grocery chains and food-service distributors. If you recently bought eggs, it’s…

Read more 12
Generic Zyrtec Recalled Over Heartburn Drug Mix-Up, July 23
📅 29 days ago

Generic Zyrtec Recalled Over Heartburn Drug Mix-Up, July 23

Generic Zyrtec recalled nationwide for cross-contamination with heartburn drug ranitidine. Four lot numbers affected. No illnesses reported yet. Call Rising Pharma at 1-844-874-7464.

Read more 12
Generic Zyrtec Recalled Over Ranitidine Contamination Risk July 23
📅 29 days ago

Generic Zyrtec Recalled Over Ranitidine Contamination Risk July 23

Generic Zyrtec cetirizine tablets recalled nationwide due to cross-contamination with ranitidine heartburn drug. Four lot numbers affected, expiring October 2028. No adverse events reported yet.

Read more 12
Swedencare (STO: SECARE) Shares Plunge 17% After Q2 Revenue Misses Analyst Estimates
📅 1 month ago

Swedencare (STO: SECARE) Shares Plunge 17% After Q2 Revenue Misses Analyst Estimates

Swedencare shares plunged 17% Wednesday after second-quarter results missed Wall Street expectations. The pet health company reported net sales of SEK 670 million for Q2 2026. That figure grew just 4% year-over-year but missed consensus estimates by 4%. Operational EBITDA reached SEK 129 million, also up 4%, yet fell 5% short of forecasts.  North America…

Read more 12

ASND News FAQ